Clinical Trial Update: Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer [NA]

View source ↗

Summary

This completed clinical trial assesses esketamine for prevention of depressive symptoms after cytoreductive surgery in patients with ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Ovarian Cancer

Drugs mentioned

• Esketamine (esketamine)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Ovarian Cancer, Cytoreductive Surgery | NA | Status: COMPLETED